Related Experiment Videos
[Ovulation induction with human menopausal gonadotropins in hypothalamic-hypophyseal disfunction]
Ginecologia Y Obstetricia De Mexico
|July 1, 1993
Summary
Human Menopausal Gonadotropins (HMG) effectively induces ovulation in anovulatory women with hypothalamic-pituitary dysfunction, even after clomiphene citrate failure. This treatment offers a viable option for achieving pregnancy in carefully monitored patients.
Area of Science:
- Reproductive Endocrinology
- Human Reproduction
- Infertility Treatment
Context:
- Anovulatory infertility
- WHO Group II dysfunction
- Previous clomiphene citrate failure
Purpose:
- Evaluate Human Menopausal Gonadotropins (HMG) efficacy
- Assess outcomes in anovulatory women
- Analyze pregnancy and complication rates
Summary:
- 180 anovulatory women with WHO Group II dysfunction received HMG treatment over three years.
- Ovulation was achieved in 81% of cycles (340/420), with a 33.8% pregnancy rate per ovulatory cycle.
- Ovarian hyperstimulation syndrome occurred in 3.5% of cycles; pregnancy and loss rates align with literature.
Impact:
- HMG is a valuable treatment for specific anovulatory infertility cases.
- Demonstrates high ovulation and pregnancy rates with manageable complication risks.
- Highlights the necessity of expert monitoring for safe and effective HMG use.